QL-008. An exploration of associations between health related quality of life and medulloblastoma molecular subgroup status in survivors from the SIOP UKCCSG PNET3 trial

Bull, Kim, Kennedy, Colin, Bailey, Simon, Ellison, David and Clifford, Steven (2014) QL-008. An exploration of associations between health related quality of life and medulloblastoma molecular subgroup status in survivors from the SIOP UKCCSG PNET3 trial. Neuro-Oncology, 16 (Suppl 1), i112, [QL-008]. (doi:10.1093/neuonc/nou079).

Abstract

OBJECTIVES: To explore the possibility of combining retrospective biological and quality of survival (QoS) data, to investigate whether health-related quality of life (HRQoL) may be related to the underlying biology of medulloblastoma. METHODS: Using available data from our previous studies of SIOP UKCCSG PNET3 survivors whose tumours had been assigned to disease molecular subgroup (SHH, WNT and non-SHH/WNT (Group 3 and Group 4) tumours) using DNA methylation and immuno-histochemical methods, and for whom HRQoL data were also available, we conducted univariate analyses to assess any differences in child- and parent-reported health status (HUI), behavioural functioning (SDQ), and HRQoL (PedsQL) between subgroups. This was followed by a three-step hierarchical forward multiple regression analysis; tumour subgroup was entered at step one followed by gender, age at diagnosis and interval from diagnosis (step two) and treatment and cerebellar mutism (step three) as predictors. Predictors were retained in the model if p < 0.1. RESULTS: There was a significant overall inter-group difference in parent-reported PedsQL (p = 0.018), due to significantly better PedsQL scores in the SHH group (median = 95.3) compared with the WNT group (median = 67.1, p = 0.015) and the non-SHH/WNT group (median = 74.0, p = 0.015). SHH trended to better functioning in all other indices used. At each step in the regression modelling, SHH remained the only significant predictor of parent-reported HRQoL, even after controlling for factors previously associated with worse HRQoL outcomes (treatment and cerebellar mutism) in the final model (B = 17.1, R2 = 0.25, p = 0.043). CONCLUSION: These initial investigations indicate combined analyses of biological and QoS data could provide new insights on HRQoL outcome, and should be incorporated into the planning of expanded studies of medulloblastoma survivors, aimed at fully establishing any basis to inform the future management of patients according to their molecular subgroup status.

This record has no associated files available for download.

Contributors

Author: Kim Bull

Download statistics